Research Topics
| Herve AllainSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's diseaseH Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
Dement Geriatr Cogn Disord 10:181-5. 1999....- [Perspectives for drug treatment in Alzheimer's disease]H Allain
Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I, 2, avenue du Pr Leon Bernard, CS 34317, 35043 Rennes Cedex, France
Ann Med Interne (Paris) 152:527-32. 2001..The main goal of the present review is to summarize the state-of-the-art for a non specialist in AD... - [Effect of almitrine/raubasine on cerebral metabolism in the elderly]H Allain
Laboratoire de Pharmacologie Expérimentale et Clinique Faculté de Médecine, Université de Rennes 1 2, avenue du Professeur Léon Bernard CS34317 35043 Rennes
Presse Med 31:562-4. 2002..This mechanism supports the effects on behaviour obtained in various animal models and the benefits observed during clinical trials in elderly patients presenting with cognitive defects... - Drug therapy of frontotemporal dementiaHerve Allain
Laboratory of Clinical and Experimental Pharmacology Faculty of Medicine, University of Rennes I, 2, avenue du Pr Leon Bernard, CS 34317, F 35043 Rennes Cedex, France
Hum Psychopharmacol 18:221-5. 2003.... - Mild cognitive impairment: a treatment at last?Herve Allain
Laboratory of Clinical and Experimental Pharmacology, Centre Mémoire Ressource Recherche de Bretagne, Faculty of Medicine University of Rennes1, France
Lancet Neurol 3:643. 2004 - [Drug distribution systems in hospitals]H Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
Therapie 57:379-84. 2002..The challenge is to optimise and secure all steps of the process. This goal needs assessment and quality control of the different phases, opening the discussion between hospital policy and regulatory and technical considerations... - Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteersH Allain
Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, CS 34317, 2, avenue du professeur Leon Bernard, 35043 Rennes, France
Psychopharmacology (Berl) 165:419-29. 2003..Dementia includes not only cognitive deficit but may also include psychiatric and behavioral symptoms. These psychological symptoms of dementia require specific treatment without deleterious effects on cognitive functions... - Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoidsHerve Allain
Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, Rennes, France
Drug Saf 27:649-60. 2004..Such a review reinforces the need for a strong international pharmacovigilance organisation using similar methods to detect and analyse the adverse effects of drugs... - The anti-dementia drugs: myth, hype or reality?Herve Allain
Laboratoire de Pharmacologie Expérimentale et Clinique et Centre Mémoire Ressources Recherche, Faculte de Medecine, Universite de Rennes I, Rennes, France
Curr Opin Neurol 16:S23-7. 2003..It remains for clinicians to confirm the authenticity of this worldwide project... - Alzheimer's disease: the pharmacological pathwayHerve Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, CS 34317, 35043 Rennes Cedex, France
Fundam Clin Pharmacol 17:419-28. 2003..The rapidity at which these compounds will be at our disposal is highly dependent on the policy of the pharmaceutical companies... - Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placeboHerve Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Universite de Rennes 1, Faculte de Medecine, 2 rue du Pr Léon Bernard, CS 34317, 35043 Rennes Cedex, France
Eur J Clin Pharmacol 59:179-88. 2003..e. usual starting doses in elderly) or placebo were administered at night to 48 healthy elderly volunteers aged 65 years or more. The study included four treatment periods separated by wash-out periods of at least 1 week... - [Mechanisms of chronic cough pathophysiology]H Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
Rev Mal Respir 21:763-8. 2004..At the CNS level, functional disturbancies and neosynaptogenesis can be described, with the intervention of the NMDA-type glutamatergic receptors... - Comparative effects of pharmacotherapy on the maintenance of cognitive functionH Allain
Department of Pharmacology, Faculte de Medecine, Universite de Rennes I, 2, avenue du professeur Leon Bernard, 35043 Rennes Cedex, France
Eur Psychiatry 16:35s-41s. 2001..As an illustration of this approach we shall relate two studies, TIATEM (phase I) and TIAGE (phase III/IV), leading to the determination of a good cognitive safety profile of an atypical neuroleptic drug, tiapride... - [An experience in teaching pharmacology on the internet]H Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes 1, 2, Av du Professeur Léon Bernard, F 35043 Rennes
Presse Med 30:1065-70. 2001..Its impact on the quality of drug therapy by future doctors remains to be determined... - Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative reviewHerve Allain
Laboratory of Experimental and Clinical Pharmacology, Pôle des Neurosciences and Centre Memory Resources Research CMRR, Faculty of Medicine, University of Rennes 1, Rennes Cedex, France
Drugs Aging 22:749-65. 2005..Comparative pharmacovigilance studies focused on the impact of hypnotics on postural stability are very much needed... - [Parkinson disease: interrogations and solutions]H Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes
Presse Med 26:909-15. 1997..The main challenge is represented by compounds potentially antagonizing cell death. In any case, the therapeutic approaches have to be guided by good quality clinical trials... - Clinical efficacy of almitrine-raubasine. An overviewH Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
Eur Neurol 39:39-44. 1998..The appropriate and usual dosage (2 tablets per day) and the good tolerance of the compound have been confirmed in a French multicentric study in 5,361 outpatients... - [Biology of motivation]Herve Allain
Departement de Pharmacologie, Centre Mémoire Ressources Recherche de Bretagne, Universite de Rennes I
Psychol Neuropsychiatr Vieil 2:167-72. 2004..Studies specifically devoted to motivation and apathy are anxiously expected and should be based on the most recent acquisitions of the neurophilosophy... - [What is dementia? 5. "Anti-dementia" drug: myth or reality?]Herve Allain
Laboratoire de pharmacologie expérimentale et clinique et centre mémoire ressources recherche CMRR, Faculte de Medecine, Universite de Rennes I
Psychol Neuropsychiatr Vieil 1:151-6. 2003..The present targets of pharmacology are directed against the decline of the neurone and of cognitive performance. Clinicians will check the accuracy of this very ambitious project... - Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairmentH Allain
CHRU de Rennes, France
Psychopharmacology (Berl) 148:361-6. 2000..The aim of the present study was to compare the efficacy and safety of tiapride versus haloperidol and placebo in the treatment of agitation and aggressiveness in elderly patients with mild or moderate mental impairment... - [Psychiatry and clinical research. A dialogue with hospital directors]H Allain
Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I
Presse Med 29:1768-72. 2000..Incentive politics as well as avoidance of technical and frequently definitive errors must be proned and issue from a deep analysis of how leading teams are organized and operate... - Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mgHerve Allain
Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, 2, avenue du professeur Leon Bernard, 35043 Rennes, CS34317, France
Hum Psychopharmacol 18:369-74. 2003..Insomniac patients tended to prefer zolpidem to zaleplon on both nocturnal and diurnal assessments. These results provide additional information for the physician's choice, based on the patient's preference for a given drug... - Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteersStéphane Schück
Laboratoire de Pharmacologie Experimentale et Clinique, Université de Rennes I Faculté de Médecine, CS 34317, 35 043 Rennes cedex, France
Fundam Clin Pharmacol 16:57-65. 2002..It is concluded that a single intravenous perfusion of piribedil 3 mg improves alertness and the information processing speed within the central nervous system, in healthy volunteers... - Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasmaOlivier Tribut
Laboratoire de Pharmacologie, Hopital de Pontchaillou, 35033 Rennes, France
Ther Drug Monit 27:265-9. 2005..This method has been in routine use in our laboratory for antiretroviral drug monitoring and now allows quantitative assay of a novel HIV protease inhibitor, atazanavir, with satisfactory intra- and interassay precision (CV<12%)... - Does rat global transient cerebral ischemia serve as an appropriate model to study emotional disturbances?Guy Bernard Bantsiele
Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, CS34317, 35043 Rennes, France
Fundam Clin Pharmacol 18:685-92. 2004.... - [Pharmacological treatment in severe dementia]Pierre Jouanny
centre mémoire de ressource et de recherche, Universite de Rennes I, France
Psychol Neuropsychiatr Vieil 3:S51-5. 2005..Medical treatment should only be co-prescribed with a global care of all co-morbidities, autonomy loss and patient's and care-giver's burden, and associated with psychological and organisational support... - Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologistsDanièle Bentué-Ferrer
Laboratoire de Pharmacologie, Faculte de Medecine, Rennes, France
CNS Drugs 17:947-63. 2003..Possible interactions involving other often coprescribed antidementia agents (e.g. memantine, antioxidants, cognitive enhancers) remain an open area requiring particularly prudent use... - Treatment of the mild cognitive impairment (MCI)Herve Allain
Laboratory of Experimental and Clinical Pharmacology and Centre Mémoire Ressources Recherche de Bretagne, Faculte de Medecine, 2 Avenue du Professeur Leon Bernard, Rennes Cedex, France
Hum Psychopharmacol 22:189-97. 2007..These three hypotheses will be presented on the basis of the neurobiology and the pharmacology, and examples of potentially active candidates will be discussed... - Effects of tiapride on electroencephalograms and cognitive functions in the elderlyA Patat
Biotrial SA, Drug Evaluation and Pharmacology Research, Rennes, France
Int Clin Psychopharmacol 14:199-208. 1999.... - Drugs and vascular dementiaHerve Allain
Laboratory of Pharmacology, Faculty of Medicine, University of Rennes I, 2 Avenue du Pr Leon Bernard, CS 34317, F 35043 Rennes Cedex, France
Dement Geriatr Cogn Disord 16:1-6. 2003..In that respect, monoamine oxidase inhibitors, and more recently acetylcholinesterase inhibitors, are in the process of being recognized as first-line treatments of established vascular dementia... - Disease-modifying drugs and Parkinson's diseaseHerve Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, 2 Av du Pr Leon Bernard, F 35043 Rennes, France
Prog Neurobiol 84:25-39. 2008..It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases... - [Mild Cognitive Impairment: potential therapeutics]H Allain
, , , CS 34317, 35043 Rennes Cedex
Rev Neurol (Paris) 158:S35-40. 2002..For that purpose, several long term clinical trials are running (antioxidants, nootropics, anticholinesterasics.) and new molecules in the pipe-line should be assessed in patients with the diagnosis of MCI... - Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approachD Bentue-Ferrer
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
Clin Neuropharmacol 13:S9-25. 1990.... - Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotilineH Allain
Experimental and Clinical Pharmacology Laboratory, Faculty of Medicine, Rennes, France
Psychopharmacology (Berl) 106:S56-61. 1992..This effect was rapid, stable, and superior to those of viloxazine and maprotiline. It may be explained by moclobemide's selective and reversible inhibition of monoamine oxidase A, as well as by the lack of any anticholinergic action... 
Impaired cognition and attention in adults: pharmacological management strategiesHerve Allain
Laboratoire de Pharmacologie Experimentale et Clinique, Pôle des Neurosciences de Rennes, Faculte de Medecine, Universite de Rennes I, France
Neuropsychiatr Dis Treat 3:103-16. 2007..Drug therapeutic strategies" for improving cognition (except for memory function) are currently rather scarce, but promising perspectives for a new neurobiological approach to cognitive pharmacology will be highlighted...- Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatographyOlivier Tribut
Laboratoire de Pharmacologie Biologique, Hopital de Pontchaillou, Rennes, France
Ther Drug Monit 24:554-62. 2002..The method has been validated extensively and has been in routine use in our laboratory for several months for drug monitoring in plasma samples from patients treated with antiretroviral drugs... - PharmacogenomicsOlivier Tribut
Department of Pharmacology, Medical Faculty, Rennes I University, France
Med Sci Monit 8:RA152-63. 2002..Progress in methods of phenotyping/genotyping should promote diagnosis, guide the choice of drug for an individual (benefit/risk ratio), and determine dosage and regimen... - Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study GroupH Allain
Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculte de Medecine, Universite de Rennes I, Rennes
Eur Neurol 44:22-30. 2000..7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups... - Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment settingHerve Allain
Hopital de Pontchaillou, Rennes, France
Seizure 16:173-84. 2007..Seizure type was the only determinant of improvement of quality of life identified. In conclusion, lamotrigine treatment is associated with improved quality of life, regardless of treatment regimen... - Gentamicin-loaded calcium carbonate materials: comparison of two drug-loading modesAnita Lucas-Girot
Institut de Chimie de Rennes, Laboratoire Chimie du Solide et Inorganique Moléculaire, UMR 6511, Cristallochimie et Biomatériaux, Universite de Rennes 1, CS 74205, Campus de Beaulieu, Bât 10B, 35042 Rennes Cedex, France
J Biomed Mater Res B Appl Biomater 73:164-70. 2005.... - A computer model of rigidity and related motor dysfunction in Parkinson's diseasePhilippe Le Cavorzin
Laboratoire de Pharmacologie Experimentale et Clinique, Faculté de médecine de Rennes, Rennes, France
Mov Disord 18:1257-65. 2003..This may lead to a search for new (spinal) pharmacological targets in PD. It emphasizes further the value of computer modeling in understanding motor control in health and disease... - Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepamD Bentue-Ferrer
Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, 2 Avenue du Pr Leon Bernard, 35043 Rennes Cedex, France
Eur Neuropsychopharmacol 11:41-50. 2001..This effect could be explained, at least in part, by increased extracellular dopamine concentrations in the striatum. Their different structures could explain the different pattern observed for the two benzodiazepines... - Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsoniansD Milon
Laboratoire de Pharmacologie Experimentale et Clinique, CHR de Rennes, France
Fundam Clin Pharmacol 4:695-705. 1990..The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction... - [Acting out and psychoactive substances: alcohol, drugs, illicit substances]C Gillet
, , , , 35043 Rennes, France
Encephale 27:351-9. 2001..In the future, a specific treatment of these deleterious phenomena will have to be considered in order to reduce drug-induced iatrogenic behavioural disorders...